Novo Nordisk CEO: Have Strong Growth Ahead in Diabetes

The transcript discusses a meeting with CEOs about US investments and regulatory changes. It highlights the potential benefits of streamlining FDA processes, the impact of H1B visa changes on talent acquisition, and the company's focus on growth in diabetes, obesity, and biopharm sectors.

In what ways does the speaker believe the pharmaceutical industry can adapt to a more protectionist world?

What future opportunities does the speaker see in the diabetes and obesity markets?